Literature DB >> 15164224

Grey-box pharmacokinetic/pharmacodynamic modelling of a euglycaemic clamp study.

Christoffer Wenzel Tornøe1, Judith L Jacobsen, Henrik Madsen.   

Abstract

Grey-box pharmacokinetic/pharmacodynamic (PK/PD) modelling is presented as a promising way of modelling the pharmacokinetics and pharmacodynamics of the in vivo system of insulin and glucose and to estimate model and derived PK/PD parameters. The concept behind grey-box modelling consists in using a priori physiological knowledge along with information from data in the estimation of model parameters. The PK/PD properties of two types of insulin are investigated in a euglycaemic clamp study where a single bolus of insulin is injected subcutaneously. The effect of insulin on the glucose disappearance is investigated by artificially maintaining a blood glucose concentration close to the normal fasting level. The infused glucose needed to maintain the clamped blood glucose concentration can therefore be used as a measure for the glucose utilization. The PK and PD parameters are successfully estimated simultaneously thereby describing the uptake, distribution, and effect of the two different types of insulin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15164224     DOI: 10.1007/s00285-003-0257-z

Source DB:  PubMed          Journal:  J Math Biol        ISSN: 0303-6812            Impact factor:   2.259


  7 in total

Review 1.  Pharmacokinetic-pharmacodynamic modeling: why?

Authors:  J Pérez-Urizar; V Granados-Soto; F J Flores-Murrieta; G Castañeda-Hernández
Journal:  Arch Med Res       Date:  2000 Nov-Dec       Impact factor: 2.235

2.  An application of Ito's lemma in population pharmacokinetics and pharmacodynamics.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  1999-04       Impact factor: 4.200

3.  Pharmacokinetic variability and therapeutic drug monitoring actions at steady state.

Authors:  M Ramanathan
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

Review 4.  Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

Authors:  B Meibohm; H Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  1997-10       Impact factor: 1.366

5.  Establishment of time-action profiles for regular and NPH insulin using pharmacodynamic modeling.

Authors:  J R Woodworth; D C Howey; R R Bowsher
Journal:  Diabetes Care       Date:  1994-01       Impact factor: 19.112

6.  Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures.

Authors:  J R Woodworth; D C Howey; R R Bowsher; R L Brunelle; H M Rowe; J Compton; B Cerimele
Journal:  Diabetes Care       Date:  1994-05       Impact factor: 19.112

7.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

  7 in total
  7 in total

1.  Non-linear mixed-effects models with stochastic differential equations: implementation of an estimation algorithm.

Authors:  Rune V Overgaard; Niclas Jonsson; Christoffer W Tornøe; Henrik Madsen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

2.  Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations.

Authors:  Chenhui Deng; Elodie L Plan; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2016-05-10       Impact factor: 2.745

3.  Modeling the euglycemic hyperinsulinemic clamp by stochastic differential equations.

Authors:  Umberto Picchini; Susanne Ditlevsen; Andrea De Gaetano
Journal:  J Math Biol       Date:  2006-10-05       Impact factor: 2.259

4.  Stochastic differential equations in NONMEM: implementation, application, and comparison with ordinary differential equations.

Authors:  Christoffer W Tornøe; Rune V Overgaard; Henrik Agersø; Henrik A Nielsen; Henrik Madsen; E Niclas Jonsson
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

Review 5.  Pharmacokinetic/pharmacodynamic modelling in diabetes mellitus.

Authors:  Cornelia B Landersdorfer; William J Jusko
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

6.  Stochastic modeling of systems mapping in pharmacogenomics.

Authors:  Zuoheng Wang; Jiangtao Luo; Guifang Fu; Zhong Wang; Rongling Wu
Journal:  Adv Drug Deliv Rev       Date:  2013-03-22       Impact factor: 15.470

7.  Modeling Variability in the Progression of Huntington's Disease A Novel Modeling Approach Applied to Structural Imaging Markers from TRACK-HD.

Authors:  J H Warner; C Sampaio
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.